Abstract
Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Current Drug Targets
Title:Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Volume: 13 Issue: 5
Author(s): Peter Brust, Dan Peters, Winnie Deuther-Conrad
Affiliation:
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Abstract: Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Export Options
About this article
Cite this article as:
Peter Brust, Dan Peters, Winnie Deuther-Conrad , Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398955
DOI https://dx.doi.org/10.2174/138945012800398955 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review
Current Neuropharmacology In Vitro Selection of a Single-Stranded DNA Molecular Recognition Element for the Pesticide Malathion
Combinatorial Chemistry & High Throughput Screening Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy A Three-gene-based Type 1 Diabetes Diagnostic Signature
Current Pharmaceutical Design Perspectives on Rational Drug Design and Therapy for Pediatric Precision Medicine
Current Medicinal Chemistry Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Ouabain-Induced Signaling and Cell Survival in SK-N-SH Neuroblastoma Cells Differentiated by Retinoic Acid
CNS & Neurological Disorders - Drug Targets Amphotericin B: From Derivatives to Covalent Targeted Conjugates
Mini-Reviews in Medicinal Chemistry Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Developing of A Novel Clinical Kit for Assaying of Alpha-fetoprotein Based on Luminescent and Magnetic Nanoparticles
Current Nanoscience Defining the Cough Spectrum and Reviewing the Evidence for Treating Non-Specific Cough in Children
Current Pediatric Reviews Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular Retinal Diseases
Current Gene Therapy